Cobra Biomanufacturing Plc (AIM:CBF) today announced its agreement with the International AIDS Vaccine Initiative (IAVI) and GlaxoSmithKline Biologicals S.A. (GSK Biologicals), for process development and manufacturing of two HIV vaccine candidates for evaluation in clinical trials. The programme is in support of a previously announced collaboration between IAVI and GSK.
